Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | DDX3X | O00571 | 1/20 | 0.42 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566653 | 1.00 | PGR (0.48) | PGRARLMNAALDH1A1KMT2A | |
| SCHEMBL24309602 | 0.91 | PGR (0.56) | PGRARLMNAALDH1A1KMT2A | |
| SCHEMBL29568117 | 0.91 | PGR (0.56) | PGRARLMNAALDH1A1KMT2A | |
| SCHEMBL29567014 | 0.86 | TSHR (0.39) | PGRLMNAALDH1A1MAPTTDP1 | |
| SCHEMBL24309292 | 0.86 | TSHR (0.39) | PGRLMNAALDH1A1MAPTTDP1 | |
| SCHEMBL24309260 | 0.86 | LMNA (0.49) | PGRARLMNAALDH1A1KMT2A | |
| SCHEMBL29566397 | 0.86 | LMNA (0.49) | PGRARLMNAALDH1A1KMT2A | |
| SCHEMBL24310315 | 0.83 | LMNA (0.46) | PGRARLMNAALDH1A1KMT2A | |
| SCHEMBL24309297 | 0.79 | PGR (0.52) | PGRARLMNAALDH1A1KMT2A | |
| SCHEMBL29567154 | 0.79 | PGR (0.52) | PGRARLMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PGR 4116/4885AR 4542/4885LMNA 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.